Kornimate/medical-research-clean huggingface dataset:
intranasal lavage with hypochlorous acid safely reduces the symptoms in the ambulatory patient with covid-19.

Conditions: COVID-19

Summary: the goal of this observational study is to determine if intranasal lavage reduces symptoms in adults with covid-19. the main question is can a hypochlorous acid solution reduce the symptoms of covid-19. participants will asked to do the following: * irrigate each nostril once a day for ten days with a hypochlorous acid solution. * write a daily record of the presence or absence of symptoms such as fever, headache, chills, nausea, or change in sense of smell. * after ten days, return the daily log in the mail to the investigator.

methods this study was approved by the institutional review board of reading hospital (irb 036-020) with informed consent obtained from all adult participants. convenience sampling methodology was utilized for those who met the study criteria inclusive to all gender at ages18 years old and/or older. excluded participants were those who expressed the desire to not use nasal lavage, women with known pregnancies, and children aged 17 years old and/or younger. the source of enrollees was generated from patients presenting to an ambulatory testing facility for nasopharyngeal swabs for covid-19. swab analysis was obtained by reverse transcription-polymerase chain reaction until the covid-19 antigen specific test (binax now, abbott lab) became available for use which allowed a more lenient process for including the covid-19 positive patients. each enrolled participant was given a nasaflo neti pot (neilmed pharmaceuticals, inc) with instructions to irrigate each nostril once a day for ten days with the provided hypochlorous solution vashe wound solution (urgo medical north america, llc). each participant began the daily 120 cc (four -ounce) nasal lavage intervention within 72 hours of their testing. each participant was given a scripted diary log in which they recorded daily the presence or absence of clinical symptoms such as elevated temperature, fatigue, headache, chills, nausea, and anosmia by noting "yes" or "no." after completing the ten days of nasal lavage, each log was returned to the principal investigator via mail. the participants remained quarantined for the recommended time period of 14 days, and adhered to social distancing, handwashing, and donning of face masks. throughout the study, each participant was urged to not share their devices with any other individuals. after thirty days from the start of their nasal intervention, participants were telephoned for a follow-up review.

Eligibility criteria:
inclusion criteria: * all gender aged 18 years and older. * positive covid-19 specific antigen test resulted within 72 hours. exclusion criteria: * persons with known current pregnancy * persons less than or equal to 17 years of age. * persons currently using any intranasal medications or agents * persons unwilling to use nasal lavage.

Keywords: intranasal lavage
effectiveness of commercial video games in subacute stroke rehabilitation

Conditions: Stroke

Summary: stroke creats dependancy of patients due to various associated impairments. the use of low-cost technologies for neurological rehabilitation may be beneficial for the treatment of these patients.

to determine the effectiveness of a structured protocol using semi-immersive virtual reality with commercial videogames for balance, postural control, functional independence, quality of life and motivation in patients who have suffered an ischemic and / or hemorrhagic stroke in subacute phase and are being treated in a mid-stay hospital. patients and methods: randomized controlled trial. simple blind. control group will receive conventional therapy (physical therapy and occupational therapy) intervention being based on a task-oriented approach, with five weekly sessions of physical therapy and occupational therapy with duration of 45 minutes per session. the experimental group will receive in addition to the above an experimental intervention during 8 weeks providing additional treatment using virtual reality semi-immersive complement is added by means of commercial video games implemented with the xbox 360º video game console in conjunction with the kinect device.

Eligibility criteria:
inclusion criteria: * patients diagnosed with cva in subacute ischemic or hemorrhagic type. * nihss scale score less than 20. * moca test with scores equal to or greater than 14 (mild cognitive impairment or absence of cognitive impairment). * modified rankin scale between 0-4. * patients with the ability to maintain autonomous sitting and standing with or without aids. * patients who have received the information document of the study and signed the informed consent form. exclusion criteria: * nihss scale scores greater than 21 . * moca test with score lower than 14. * modified rankin scale between 5-6. * patients without the ability to maintain autonomous sitting. * patients who refused to sign the informed consent form. * hospital discharge expected at the beginning of the study. * patients who at any time have shown worsening of the general state, disinterest or desire to leave the study. * pathologies susceptible to worsening or contraindication with virtual reality devices and commercial video games: * photosensitive epilepsy. * modified ashworth scale greater than 2. * moderate-severe cognitive impairment. * visual alterations. * non-collaborating patient. * behavioral alterations. * refusal to treatment with vr systems. * presence of other neurological pathologies. * other cardiovascular diseases that contraindicate physical exercise. * visual or auditory, musculoskeletal, bone or joint alterations in acute or chronic phase that could influence the primary pathology.

Keywords: balance baropodometry video games virtual reality
the effect of mindfulness stress reduction program on menopausal complaints and quality of life

Conditions: Postmenopausal Women

Summary: the study was conducted to determine the effect of the mindfulness stress reduction program (mbsr) applied to postmenopausal women on menopausal complaints and quality of life. the population of the study was 2626 women and the sample was composed of 55 experimental and 63 control groups, totally 118 women. the data of the study were collected using personal information form, mindful attention awareness scale (maas), menopausal symptoms assessment scale (msas) and menopause specific quality of life scale (myqol).

aim: the study was conducted to determine the effect of the mindfulness stress reduction program (mbsr) applied to postmenopausal women on menopausal complaints and quality of life. materials and methods: research is quasi-experimental. the population of the study was 2626 women and the sample was composed of 55 experimental and 63 control groups, totally 118 women. the data of the study were collected using personal information form, mindful attention awareness scale (maas), menopausal symptoms assessment scale (msas) and menopause specific quality of life scale (myqol). in the study, an 8-week mindfulness stress reduction program was applied to the women in the experimental group. in the study, mid-test and post-test (maas, msas, myqol) were applied 8 and 16 weeks after the pre-test. descriptive statistics, independent groups t test, chi-square test, anova, mauchly's test and cronbach alpha analysis were used to evaluate the data.

Eligibility criteria:
inclusion criteria: being in menopause * not having any diagnosed psychiatric disease or using medication, * not using or not using hormone replacement therapy. exclusion criteria: * having entered menopause with surgical methods, * not attending at least two group programs.
assessment of the effects on the skin microbiome of amending an over-the-counter eczema product with activated oil (ao)

Conditions: Eczema

Summary: this is a single-center, randomized, blinded, controlled trial assessing the effects on the skin microbiome in patients with eczema of amending a standard-of-care (soc), over-the-counter (otc) topical colloidal oatmeal formulation with a modified plant oil ("activated oil", ao)


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form. * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female subjects aged who have a recent eczema itch flareup and/or pre-flare-up symptoms at screening as determined by visual analog scale (vas). * diagnosis of mild to moderate eczema (grade 3 - 7 on the rajka-langeland severity index). * having a target lesion with an adsi score of 6-12 and an erythema and pruritus subscore of ³2 (moderate). * generally good health based on reported history. * able to discontinue all medical and over the counter topical emollients, moisturizers, and / or other skin barrier lotions. * females of child-bearing potential should agree to continue using a medically acceptable method of birth control throughout the study and for 30 days immediately after the last dose of study drug. * ability to administer topical medication and be willing to adhere to the study interventions. * agreement to adhere to lifestyle considerations throughout the duration of the study. exclusion criteria: * pregnancy or lactation. * any type of malignancy involving the study site area (lesion or non-lesion site) in the last 5 years. * known allergy to hydrocortisone or topical antibiotic. * topical or oral use of an antibiotic within the last 7 days prior to baseline clinical visit. * bleach bathing in the 7 days prior to baseline clinical visit. * current use of class i-iii topical corticosteroids or systemic medications (e.g. dupixent) potentially affecting eczema or the skin. * surgeries or invasive medical procedures planned during course of study. * suspected non-compliance or non-cooperation. * intake of experimental drugs or experimental topical skin treatments within 30 days prior to study start. * mental disability or any other lack of fitness, in the investigator's opinion, to preclude subject's participation in or ability to complete the study. * diagnosis of human immunodeficiency virus in medical history.
effect of ranibizumab on malignant conjunctival neoplasia

Conditions: Conjunctival Neoplasms

Summary: the purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.

ranibizumab is a recently approved vascular endothelial growth factor (vegf) inhibitor shown to be effective in treating exudative macular degeneration. its analog, avastin has also been employed to treat macular edema, proliferative diabetic retinopathy and wet age related macular degeneration. ranibizumab binds to and inhibits vascular endothelial growth factor a (vegf-a), which has been shown to cause neovascularization and leakage in models of ocular angiogenesis. binding to vegf-a prevents ranibizumab's interaction with vegfr-1 and -2 receptors on the surface of endothelial cells, thereby reducing proliferation, vascular leakage, and angiogenesis. given that conjunctival tumors require the formation of new blood vessels to supply the proliferating cells, we propose a study to evaluate the effect of subconjunctival ranibizumab as a primary intervention in patients with conjunctival tumors.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age \> 21 years * tumors whose treatment with standard therapy would cause significant visual morbidity * diagnosis of biopsy proven malignant conjunctival neoplasia and are * recurrent disease * multi-focal disease * diffuse disease exclusion criteria: * extension of tumor into eye or orbit. * regional spread or metastatic disease * pregnancy (positive pregnancy test) or lactation. * premenopausal women not using adequate contraception. the following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an iud, or contraceptive hormone implant or patch. * current infection or inflammation in either eye * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * participation in another simultaneous medical investigation or trial
a study to compare the pharmacokinetics of different oral formulations of fdl169 in healthy subjects

Conditions: Cystic Fibrosis

Summary: this is a randomised, cross-over study comprised of 6 periods in healthy subjects.subjects will receive regimens a, b and c in a randomised crossover manner in the fed state, followed by regimens d, e and f in a randomised crossover manner, in the fasted or fed state, as applicable.

this is a single centre, randomised, cross-over study comprised of 6 periods in healthy males and females.subjects will receive regimens a, b and c in a randomised crossover manner in the fed state, followed by regimens d, e and f in a randomised crossover manner, in the fasted or fed state, as applicable.

Eligibility criteria:
inclusion criteria: * healthy male and non-pregnant, non-lactating female subjects * aged 18 to 55 years * body mass index of 18.0 to 32.0 kg/m2 * must agree to the use of an adequate method of contraception exclusion criteria: * subjects who have received any imp in a clinical research study within the previous 3 months * history of any drug or alcohol abuse in the past 2 years * current smokers and those who have smoked within the last 12 months. * alkaline phosphatase, aspartate aminotransferase and/or alanine aminotransferase level \>1.5 x upper limit of normal at screening * abnormal renal function at screening * clinically significant abnormal biochemistry, haematology, coagulation profile or urinalysis * positive hepatitis b surface antigen (hbsag), hepatitis c virus antibody (hcv ab) or human immunodeficiency virus (hiv) results * history of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gi disease, neurological or psychiatric disorder. * subjects with a history of gall stones or abdominal surgery eg cholecystectomy * serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedy (including known inhibitors or inducers of cyp3a4

Keywords: cystic fibrosis
a trial to study of the effects of eletriptan 40mg on mild vs moderate to severe pain intensity of migraine

Conditions: Migraine

Summary: to evaluate the efficacy of early intervention (dosing within 2 hours of onset of the migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of migraine.


Eligibility criteria:
inclusion criteria: * diagnosis of migraine with or without aura according to the recent ihs criteria. * migraine headaches must have been present for more than one year. * history in the last 3 months of 1 to 4 acute attacks of migraine headache per month. exclusion criteria: * subjects with current or past history of coronary artery disease. * pregnant or breastfeeding women. * subjects who have chronic daily headaches.
safety and efficacy of valiant mona lsa stent graft system

Conditions: Thoracic Aortic Aneurysms

Summary: the valiant mona lsa thoracic stent graft system is for the endovascular repair of aneurysms of the descending thoracic aorta (dta) in patients who require coverage of the left subclavian artery (lsa).the study is intended to assess safety and performance of the device acutely and at 30 days.


Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age. * the subject or legal guardian understands the nature of the study and agrees to its provisions on a written informed consent form * subject must be considered a candidate for revascularization of the lsa. * subject has a dta which will require coverage of the lsa * subject's anatomy must meet the anatomical criteria to receive that implanted device exclusion criteria: * subject has had previous endovascular repair of the ascending and/or descending thoracic aorta. * subject is in acute renal failure or has renal insufficiency with a serum creatinine ≥ 2.0 mg/dl * subject is a pregnant female. * enrollment in another clinical study * subject has had a cerebral vascular accident (cva)or myocardial infarction (mi) within 3 months. * subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion. * subject has a known allergy or intolerance to the device components. * subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.

Keywords: thoracic aneurysm endovascular aortic repair tevar
cryotherapy efficacy during pulp therapy of the mandibular first permanent molars in children

Conditions: Cryotherapy Effect; Irreversible Pulpitis; Pain

Summary: the aim of the study is to assess the efficacy of cryotherapy application on the success of inferior alveolar nerve block (ianb) in reducing pain during pulp therapy of the mandibular first permanent molars with irreversible pulpitis (ip) in children age from 7 to 16 years. the null hypothesis (h0) supposed no difference in pain intensity during pulp therapy of primary molars with ip anesthetized with ianb with and without cryotherapy application. the secondary aim was to evaluate the children's behavior before and after pulpectomy in the two groups.


Eligibility criteria:
inclusion criteria: * healthy children aged 9-17 years who were categorized as class i or ii according to the asa classification. * cooperative children (rate 3 or 4 according to frankl behavior rating scale) * presence of a vital mandibular first permanent molar with sip, the tooth should show deep caries or dental restorations with a history of spontaneous lingered pain precipitated by thermal stimuli. to confirm the diagnosis of irreversible pulpitis, early response to electric pulp and thermal testing was performed. * no radiographic changes with at least two-thirds of the root must be evident. exclusion criteria: * children with severe emotional, intellectual, and behavioral difficulties. * necrotic pulp of primary molars. * unrestorable crowns * positive history of gingival swelling, abnormal mobility, and fistulous tract. * presence of radiographic signs of periapical and/or furcation radiolucency, and pathological resorption.
azacitidine and homoharringtonine in jmml

Conditions: JMML

Summary: juvenile myelomonocytic leukemia (jmml) has a poor prognosis in general, with hematopoietic stem cell transplant (hsct) remaining the standard of care for cure. azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (aml). however, the efficacy of these agents has not been elucidated in children with jmml. the primary objective is to assess the treatment effect on response rate in this subject population.


Eligibility criteria:
inclusion criteria: * newly diagnosed jmml, with pb and bm confirming diagnosis prior to informed consent signature, with one of the following: 1. somatic mutation in ptpn11 2. somatic mutation in kras 3. somatic mutation in nras and hbf % \> 5x normal value for age 4. clinical diagnosis of neurofibromatosis type 1. exclusion criteria: * 1. any condition that would prevent the subject from participating in the study. 2. any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if participated in the study. 3. any condition that confounds the ability to interpret data from the study.
clinical trial comparing two protocols using intravenous (iv) hydromorphone

Conditions: Acute Pain

Summary: the purpose of this study is to compare two opioid protocols ("h2o" and "1+1") for the treatment of acute severe pain in the emergency department. the investigators primary hypothesis is that the "h2o" protocol will be more efficacious than the "1+1" protocol in emergency department patients aged 21-64 years. the primary outcome is the proportion of patients in each arm who choose to forgo additional pain medication at 60 minutes.


Eligibility criteria:
inclusion criteria: 1. age greater than 21 years and less than 65 years: this is a study of non-elderly adult patients. in addition, patients aged 21 years and younger are automatically triaged to the children's emergency department (ed). 2. pain with onset within 7 days: pain within seven days is the definition of acute pain that has been used in ed literature. 3. ed attending physician's judgment that patient's pain warrants intravenous (iv) opioids exclusion criteria: 1. use of other opioids or tramadol within past 24 hours: to avoid introducing assembly bias related to recent opioid use, since this may affect baseline levels of pain and need for analgesics. 2. prior adverse reaction to opioids. 3. chronic pain syndrome: frequently recurrent or daily pain for at least 3 months results in modulation of pain perception which is thought to be due to down-regulation of pain receptors. examples of chronic pain syndromes include sickle cell anemia, osteoarthritis, fibromyalgia, and peripheral neuropathies. 4. alcohol intoxication: the presence of alcohol intoxication as judged by the treating physician may alter pain perception. 5. systolic blood pressure \<90 mm hg: opioids can produce peripheral vasodilation that may result in orthostatic hypotension. 6. oxygen saturation \< 95% on room air: for this study, oxygen saturation must be 95% or above on room air in order to be enrolled. 7. use of monoamine oxidase (mao) inhibitors in past 30 days: mao inhibitors have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant respiratory depression or coma. 8. co2 measurement greater than 46: in accordance with standard protocol, three subsets of patients will have their co2 measured using a handheld capnometer prior to enrollment in the study. if the co2 measurement is greater than 46 then the patient will be excluded from the study. the 3 subsets are as follows: * all patients who have a history of chronic obstructive pulmonary disease (copd) * all patients who report a history of asthma together with greater than a 20 pack-year smoking history * all patients reporting less than a 20 pack-year smoking history who are having an asthma exacerbation

Keywords: acute pain emergency department hydromorphone